Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561061
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Zinc for Infection Prevention in Sickle Cell Anemia-2 ZIPS-2
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Zinc for Infection Prevention in Sickle Cell Anemia-2
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZIPS-2
Brief Summary:
A randomized double-blinded placebo-controlled trial of zinc to reduce the incidence of severe or invasive infections in Ugandan children with sickle cell anemia SCA
Detailed Description:
The study will be a randomized placebo-controlled double blind clinical trial in which 100 Ugandan children 100-499 years of age with SCA will receive zinc 20 mg oral dispersible tablet daily or placebo identical to zinc in appearance for 6 months The primary study outcome will be incidence of infection all causes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None